3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
22
Recurrence
4
Neoplasms
3
Plasmablastic Lymphoma
2
Leukemia, Myeloid, Acute
2
Smoldering Multiple Myeloma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmacytoma
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Plasma Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pomalidomide
1
daratumumab
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmacytoma
×
daratumumab
×
30 days
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts